Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AccuVAC-PT009
- Development stage
- Preclinical
- Lead developer
- Defence Therapeutics
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
01
Overview
AccuVAC-PT009 is an investigational **protein-based prophylactic human papillomavirus vaccine** being developed by Defence Therapeutics using its ACCUM platform to enhance intracellular delivery and accumulation of vaccine antigens in target cells. The candidate is described as containing the same nine HPV-derived proteins represented in Gardasil-9, with preclinical data indicating markedly increased immunogenicity versus Gardasil-9, including substantially higher antibody titers after immunization. It is intended for prevention of HPV infection and HPV-associated diseases and remains a preclinical biologic vaccine program.
Beyond the preview
Go deeper on AccuVAC-PT009.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AccuVAC-PT009.